The revenue beat and margin improvement signal the transformation plan is gaining traction, but the company's negative equity and ongoing ATM dilution cap the upside. Monitor Q3 2026 for TrinScreen HIV order fulfillment and UniGold HIV scale-up completion, which are critical to achieving positive EBITDA and cash flow.
Price Chart
Executive Summary
Trinity Biotech reported Q1 2026 revenue of $10.8M (up 43% YoY from $7.6M), driven by rapid HIV and hemoglobin product sales, with gross margin improving to 35.4% from 25.2%. Net loss narrowed to $4.4M from $8.8M, and adjusted EBITDA improved to -$1.1M from -$4.0M. The company also announced orders for over 2 million TrinScreen HIV tests for Q3 2026 fulfillment, supporting its transformation plan. However, the company remains deeply unprofitable with negative equity and a recent ATM offering for up to $4.35M, highlighting ongoing capital needs.
Key Facts
- Q1 2026 revenue increased 43% to $10.8M from $7.6M in Q1 2025
- Gross margin improved to 35.4% from 25.2%
- Net loss of $4.4M vs $8.8M in Q1 2025
- Adjusted EBITDA of -$1.1M vs -$4.0M in Q1 2025
- Received orders for over 2 million TrinScreen HIV tests for Q3 2026
- Rapid HIV sales of $3.7M in Q1 2026, including $2.3M TrinScreen HIV vs $0.4M in Q1 2025
- Hemoglobin product sales rose to $3.3M from $2.3M in Q1 2025
- Company filed 424B5 on June 12, 2026 for up to $4.35M ATM offering
- Negative shareholders' equity of -$72M as of Dec 31, 2025 per prior filing
Financial Impact
Revenue growth of 43% YoY to $10.8M, net loss improvement of $4.4M, and gross margin expansion of 10.2 percentage points
Risk Factors
- Nasdaq delisting risk due to negative equity and low market cap
- Continued dilution from ATM offering and convertible obligations
- Execution risk on outsourced manufacturing scale-up
- Dependence on international aid funding for HIV test demand
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001554855-26-001366 |
| Document: MainDocument.htm | 0001554855-26-001366 |
| Document: 0001554855-26-001366-index-headers.html | 0001554855-26-001366 |
| Document: 0001554855-26-001366-index.html | 0001554855-26-001366 |
| Document: 0001554855-26-001366.txt | 0001554855-26-001366 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 5, 2026 22d ago | 6-K | $5.77 | awaiting T+60 | — | $7.25 (+25.62%) |
Sep 9, 2026 6w ago | 6-K | $8.00 | awaiting T+60 | — | $7.25 (−9.39%) |
Sep 2, 2026 7w ago | EFFECT | $9.60 | awaiting T+60 | — | $7.25 (−24.50%) |
Aug 28, 2026 8w ago | 6-K | $9.87 | awaiting T+60 | — | $7.25 (+26.56%) |
Aug 21, 2026 9w ago | F-1/A | $10.60 | awaiting T+60 | — | $7.25 (−31.62%) |
Aug 17, 2026 10w ago | 6-K | $11.17 | awaiting T+60 | — | $7.25 (−35.11%) |
Aug 14, 2026 10w ago | 6-K | $11.67 | awaiting T+60 | — | $7.25 (−37.89%) |
Jul 22, 2026 13w ago | 6-K | $0.3033 $0.2643 | ▼ −12.85% | ▼ −16.11% | $7.25 (+2289.85%) |
Jul 22, 2026 13w ago | 6-K | $0.3033 $0.2643 | ▼ −12.85% | ▼ −16.11% | $7.25 (+2289.85%) |
Jul 2, 2026 16w ago | 6-K | $0.3765 $0.2240 | ▼ −40.50% | ▼ −43.30% | $7.25 (+1825.21%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers